Related by context. Frequent words. (Click for all words.) 65 % CI #.#-#.# [003] 65 HSCT 64 FOLFOX4 63 metastatic lung cancer 63 liver transplant recipients 62 ischemic cardiomyopathy 61 Arch Intern Med 61 heavily pretreated 61 Engerix B 61 lipid lowering therapy 61 mRCC 61 Median survival 61 chlorambucil 61 beta blocker therapy 60 renal transplantation 60 metastatic hormone refractory 60 allogeneic stem cell 60 fluvastatin 60 azacitidine 60 relapsing multiple sclerosis 60 #mg/day [001] 60 Amrubicin 60 retrospective cohort study 60 RRMS patients 60 prospective observational 60 biochemical recurrence 60 aprepitant 59 ximelagatran 59 HER2 positive metastatic breast 59 CMV disease 59 lanthanum carbonate 59 nephrectomy 59 SHPT 59 multicenter Phase 59 esophagectomy 59 relapsed refractory multiple myeloma 59 tamoxifen therapy 59 liver biopsies 59 mg kg dose 59 % CI #.#-#.# [007] 59 placebo controlled clinical 59 chemoradiotherapy 59 lung metastases 59 Torisel 59 PREZISTA r 59 prospectively defined 59 IV melanoma 59 virologic failure 59 primary hypercholesterolemia 59 HIV uninfected 58 docetaxel chemotherapy 58 renal transplant 58 undergoing coronary artery 58 plus prednisone 58 heavily pretreated patients 58 mycophenolate mofetil 58 GSK# [001] 58 radical nephrectomy 58 pyelonephritis 58 patients evaluable 58 undetectable HCV RNA 58 metastatic renal cell carcinoma 58 decitabine 58 plus dexamethasone 58 median CD4 58 clinically meaningful improvement 58 olmesartan 58 doripenem 58 T2DM 58 colectomy 58 androgen deprivation 58 poor metabolizers 58 mcg dose 57 NHANES III 57 adenotonsillectomy 57 HBeAg positive 57 KRAS wild 57 stable angina 57 multiple myeloma MM 57 IV metastatic melanoma 57 normotensive 57 superficial bladder cancer 57 coronary revascularization 57 leukemia ALL 57 HCV infected 57 diagnosed GBM 57 cholinesterase inhibitor 57 blinded placebo controlled 57 neoadjuvant 57 evaluable 57 warfarin therapy 57 pancreatic neuroendocrine tumors 57 pancreatic insufficiency 57 coinfected 57 placebo controlled clinical trials 57 NYHA Class II 57 retinal vein occlusion 57 KRAS mutations 57 relapsed multiple myeloma 57 J Clin Oncol 57 RECIST criteria